Assessing the reporting quality of early phase dose-finding trials

被引：7
|
作者：
Yap, C. [1 ]
Solovyeva, O. [2 ]
Yin, Z. [2 ]
Martin, J. [3 ]
Manickavasagar, T. [3 ]
Weir, C. [4 ]
Lee, S. [5 ]
Dimairo, M. [6 ]
Liu, R. [7 ]
Kightley, A. [8 ]
de Bono, J. S. [9 ]
机构：
[1] ICR Inst Canc Res, Clin Trials Biostat Dept, North Site, London, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Drug Dev Unit, London, England
[4] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Univ Sheffield, Clin Trials Res Unit, Sheffield, S Yorkshire, England
[7] Bristol Meyers Squibb, Oncol, New York, NY USA
[8] Patient & Publ Involvement Partner, Lichfield, England
[9] ICR Inst Canc Res, Drug Dev Unit, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
53P
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [21] SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
    Ursino, Moreno
    Villacampa, Guillermo
    Rekowski, Jan
    Dimairo, Munyaradzi
    Solovyeva, Olga
    Ashby, Deborah
    Berlin, Jordan
    Boix, Oliver
    Calvert, Melanie
    Chan, An-Wen
    Coschi, Courtney H.
    Evans, Thomas R. Jeffry
    Garrett-Mayer, Elizabeth
    Golub, Robert M.
    Guo, Christina
    Hayward, Kathryn S.
    Hopewell, Sally
    Isaacs, John D.
    Ivy, S. Percy
    Jaki, Thomas
    Kholmanskikh, Olga
    Kightley, Andrew
    Lee, Shing
    Liu, Rong
    Mander, Adrian
    Marshall, Lynley, V
    Matcham, James
    Patel, Dhrusti
    Peck, Richard
    Rantell, Khadija Rerhou
    Richards, Dawn P.
    Rouhifard, Mahtab
    Seymour, Lesley
    Tanaka, Yoshiya
    Weir, Christopher J.
    de Bono, Johann
    Yap, Christina
    ECLINICALMEDICINE, 2025, 79
  • [22] An adaptive model switching approach for phase I dose-finding trials
    Daimon, Takashi
    Zohar, Sarah
    PHARMACEUTICAL STATISTICS, 2013, 12 (04) : 225 - 232
  • [23] Two-stage designs for Phase 2 dose-finding trials
    Ivanova, Anastasia
    Xiao, Changfu
    Tymofyeyev, Yevgen
    STATISTICS IN MEDICINE, 2012, 31 (24) : 2872 - 2881
  • [24] REEVALUATION OF DECISIONS ON THE RECOMMENDED DOSE FROM PHASE-III DOSE-FINDING TRIALS
    ROHMEL, J
    STATISTICS IN MEDICINE, 1995, 14 (9-10) : 895 - 895
  • [25] A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
    Doussau, A.
    Thiebaut, R.
    Geoerger, B.
    Schoffski, P.
    Floquet, A.
    Le Deley, M. C.
    Mathoulin-Pelissier, S.
    Rizzo, E.
    Fumoleau, P.
    Le Tourneau, C.
    Paoletti, X.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 422 - 428
  • [26] DOSE-FINDING TRIALS OF ORAL OXAMNIQUINE IN RHODESIA
    CLARKE, VDV
    BLAIR, DM
    WEBER, MC
    GARNETT, PA
    SOUTH AFRICAN MEDICAL JOURNAL, 1976, 50 (46): : 1867 - 1871
  • [27] Controlled amplification in oncology dose-finding trials
    Dehbi, Hakim-Moulay
    O'Quigley, John
    Iasonos, Alexia
    CONTEMPORARY CLINICAL TRIALS, 2023, 125
  • [28] Controlled backfill in oncology dose-finding trials
    Dehbi, Hakim-Moulay
    O'Quigley, John
    Iasonos, Alexia
    CONTEMPORARY CLINICAL TRIALS, 2021, 111
  • [29] Bayesian Adaptive Randomization in Dose-Finding Trials
    Ventz, Steffen
    Alexander, Brian M.
    Trippa, Lorenzo
    JAMA NETWORK OPEN, 2018, 1 (08)
  • [30] Optimal Stopping of Adaptive Dose-Finding Trials
    Nasrollahzadeh, Amir Ali
    Khademi, Amin
    SERVICE SCIENCE, 2020, 12 (2-3) : 80 - 99
12345